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progression, but not adhesion capability. Bone stromal cells should 
secret some growth factors although not identiﬁed by ELISA, which 
promoted the proliferation of high bone metastasis potential cells. The 
high through-out assay, 2D gel followed by mass spectromics, is cur-
rently ongoing to recognize the effective factors. 
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There is a clear need to develop effective chemoprevention strategies 
to reduce the high incidence of lung cancer. The purpose of this study 
was to evaluate the effectiveness of two targeted approaches, reversal 
of gene silencing through demethylation therapy and the induction of 
apoptosis through activation of the PPAR-γ pathway. A chemopreven-
tion study was designed in which A/J mice, which are highly suscep-
tible to lung cancer, were treated with the tobacco carcinogen NNK. 
Animals were held for 42 weeks to allow the development of pre-inva-
sive lesions: alveolar hyperplasias and adenomas. Then were separated 
into 12 groups of 15 mice and treated for 6 weeks with individual 
or a combination of the agents [hydralazine (Hyd), selenium (Se), 
sodium phenylbutyrate (PheB), valproic acid (VPA), iloprost (Ilo), and 
rosiglitazone (Ros)]. Following sacriﬁce, the number of lesions was 
determined for each animal by evaluating H&E stained sections that 
included all lung lobes. Lesions were classiﬁed as hyperplasia, ad-
enoma, or carcinoma. The most dramatic effects on tumor progression 
were seen in the groups in which Ros was administered. The number of 
hyperplasias increased by 52%, while the number of adenomas was de-
creased by 31% (p < 0.05) with Ros treatment alone compared to sham. 
The combination of Ros with Se, Hyd, and PheB resulted in a decrease 
in adenomas by 38%. The area and volume of hyperplasias and adeno-
mas from sham and treatment groups were then quantiﬁed. Volume of 
the hyperplasias and adenomas decreased by 42% and 67%, respec-
tively (p < 0.005) in the combination therapy group. Additionally, a 
companion study using nude mice was also under-taken to evaluate the 
effects of Ros on tumor growth rates. In this study 72 nude mice were 
divided into 4 groups of 18 mice and inoculated with one of 4 cancer 
cell lines (IO33, CL25, H23, and H125). Within these groups the mice 
were divided into 6 sub-groups of 3 mice each according to treatment 
plans (Sham, Se, Ros, PheB, Ros+PheB, and Ros+PheB+Hyd). Tumor 
growth, in terms of total area of tumors, for each sub-group was charted 
over a 4 week period after which the mice were sacriﬁced. Preliminary 
statistical studies have already shown high degree of correlation with 
our previous work. Of note is that within the H125 cell line; the combi-
nation of Ros+PheB retards the progression of tumor growth compared 
to sham with a difference in average total area of -286 mm2 (p< 0.02; 
CI: -513.3 to -58.7 mm2). These studies provide a strong indication that 
Ros treatment alone and in combination with PheB can dramatically 
affect lung tumor development by blocking the progression of hyper-
plasias to adenomas and through affecting the clonal expansion of these 
lesions. These ﬁndings could ultimately lead to a new chemoprevention 
strategy for lung cancer. (Supported by a fellowship from IASLC).
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Background: Development of molecularly targeted kinase inhibi-
tors against epidermal growth factor receptor (EGFR) represents a 
major therapeutic advance in treatment of non-small cell lung cancer 
(NSCLC). Kinase domain mutations of the EGFR gene, most com-
monly L858R (exon 21) and short in-frame deletions in exon 19, have 
been shown to confer general sensitivity towards the EGFR kinase 
inhibitors geﬁtinib and erlotinib. Other less frequently identiﬁed muta-
tions are much less well characterized. We recently described a unique 
somatic mutation, E884K (exon 22), that occurred in combination with 
the L858R mutation (L858R+E884K) in a patient with erlotinib-refrac-
tory stage IV NSCLC. This patient’s leptomeningeal metastases had a 
striking response to geﬁtinib monotherapy. We hypothesized that EGFR 
kinase mutations can work in concert to differentially alter kinase 
inhibitor sensitivity and downstream signaling. 
Method: We generated transfects of Cos-7 cells expressing the follow-
ing mutant EGFR constructs for signaling and kinase inhibition studies: 
(1) wild type, (2) L858R, (3) E884K, (4) L858R+E884K and (5) 
L858R+R958D. Standard phospho-immunoblotting with phosphospe-
ciﬁc antibodies was used in to study mutant EGFR signaling in vitro. 
EGFR kinase inhibition studies were performed with the EGFR vari-
ants using erlotinib, geﬁtinib and dual EGFR/ERBB2 small molecule 
inhibitors. Molecular modeling and bioinformatics sequence analysis 
was performed to understand the structural mechanism of the effect of 
E884K-EGFR.
Results: We show that E884K worked in concert with L858R and al-
tered sensitivity to kinase inhibitors and mutant receptor signaling. Mu-
tation of E884 to lysine disrupts an ion pair with residue R958 in the 
EGFR kinase domain C-lobe, an interaction that is highly conserved 
within the human kinome, many of which are “druggable targets”, 
demonstrated by our sequence analysis and structural modeling. When 
in cis with L858R, the E884K-EGFR mutation desensitized, in a domi-
nant fashion, the mutant receptor to erlotinib, while further sensitizing 
the receptor to geﬁtinib and an EGFR/ERBB2 dual inhibitor with cor-
responding inhibition of p-EGFR and downstream signaling inhibition 
of p-AKT and p-STAT3. Inhibitor sensitivity modulation similar to that 
seen with E884K was observed with the R958D mutation that should 
also disrupt the conserved ion pair. Both alone and in cis, the E884K 
mutation was activating with speciﬁc cellular phosphoproteome activa-
tion pattern and downstream signaling regulation distinct from that of 
L858R alone. 
Conclusion: E884K-EGFR mutation worked in concert with L858R 
in cis to differentially alter sensitivity to speciﬁc kinase inhibitors and 
selective downstream phosphoproteomic signaling activation. Our ﬁnd-
ings suggest that mutations of the conserved ion pair E884-R958 may 
result in conformational changes that alter kinase substrate recognition. 
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Improved efﬁcacy of targeted kinase inhibitors may be achieved by 
targeting the dominant activating mutations present.
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Background: MET belongs to the semaphorin superfamily of signaling 
proteins, containing three protein families (semaphorins, plexins, MET 
and RON) that have central roles in cell signaling. The MET receptor 
tyrosine kinase is involved in regulating cell growth/proliferation, sur-
vival, angiogenesis, cell scattering, cell motility and migration. Muta-
tions in MET have been identiﬁed in various human cancers including 
lung cancer and papillary renal cell carcinomas. MET mutations occur 
within the extracellular seven-blade β-propeller fold sema domain 
(E168D, L229F, S325G, N375S), the juxtamembrane domain (R988C, 
T1010I), and the kinase domain (M1268T). We hypothesized that these 
mutations would have differential effects on the kinase inhibition.
Methods: We modeled the various MET mutations from different 
functional domains of the receptor using Cos-7 transfection cell system 
to determine their effect on MET signaling and sensitivity to a selec-
tive MET kinase inhibitor SU11274. Sensitivity to SU11274 inhibi-
tion was assayed by phospho-immunoblotting using phospho-speciﬁc 
antibody against the major tyrosine kinase phosphorylation epitopes 
pY1234/1235 of the MET kinase in vitro.
Results: First, we identiﬁed that mutations in the sema and juxta-
membrane domain were activating as deﬁned by ligand-independent 
constitutive receptor activation. SU11274 was capable of inhibiting 
ligand induced signaling through the wild-type MET as well as mutant 
MET receptors harboring mutations in the sema, juxtamembrane and 
tyrosine kinase domain. However, SU11274 inhibition of mutant MET 
was mutation-dependent, with the juxtamembrane domain mutations 
R988C and T1010I resulting in a receptor form that was less sensitive 
to SU11274. Mutations in the sema and kinase domain also resulted 
in varying sensitivity to inhibition by SU11274 inhibition. Interest-
ingly, the kinase domain L1243R mutation in MET (homologous to the 
epidermal growth factor receptor L858R-EGFR sensitizing muta-
tion in lung cancer) substantially sensitized the mutant MET receptor 
to SU11274 inhibition with complete p-MET inhibition at 0.5 μM 
compared to 5 μM as in wild type. On the other hand, the activating 
M1268T mutation in the kinase domain was less sensitive to SU11274 
than the wild type receptor.
Conclusion: Mutations in the sema and juxtamembrane domain 
of MET result in receptor activation. The small molecule inhibi-
tor SU11274 is active against wild type and various mutated MET 
receptor. Further studies to characterize the signaling effects and the 
mechanism of sensitivity and resistance of MET mutations to speciﬁc 
inhibitors are crucial in the successful development of therapeutic MET 
inhibitors in personalized cancer therapy.
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Introduction: One of the basic exogenous factors of lung cancer 
incidence is smoking. On the other hand, hereditary predisposition in 
particular, genetic polymorphism of enzymes, plays an important part 
in development of oncologic diseases. The important role in oncopath-
ology emergence is assigned to glutathiontransferases (GST), because 
these enzymes are involved in detoxication of reactive metabolites. 
Mutations in detoxication genes are also known to be accompanied by 
the change in the cytogenetic parameter level, which are attributed to 
cytogenetic markers of early carcinogenesis stages. 
The interrelation between GSTT1 polymorphism and the chromosome 
aberrations level was analyzed in peripheral blood lymphocytes (PBL) 
and lung tissues of non-small-celled lung cancer (NSCLC) patients.
Materials and Methods: The frequencies of GSTT1 gene polymor-
phic alleles were investigated using a polymerase chain reaction in 49 
NSCLC patients. 
For cytogenetic research the interphase analysis of somatic cells 
without cultivation was used. The frequency of cells with micronuclei 
was estimated in PBL and in lung cells from nontumour tissues of lung 
cancer patients.
Results and Discussion: Analysis of GSTT1-gene polymorphism has 
shown that GSTT1(-) genotype occurred signiﬁcantly more often in 
NSCLC patients (26,6%) than in the control (4%). The study on genetic 
GSTT1 polymorphism with due account of the smoking factor has 
demonstrated that the GSTT1(-) genotype was observed with statistical 
signiﬁcance 1,5-fold more often (36,4%) in the group of non-smoking 
patients than among smoking ones - 23,7%. It is interesting that such 
regularity was revealed by other researchers for many others genes of 
xenobiotic biotransformation enzymes. 
The obtained data of the cytogenetic analysis in different tissues 
of oncologic patients were estimated by us with due account of the 
smoking factor and the genotype. In non-smoking patients, the level 
of cells with micronuclei in PBL was twice as high in the patients 
with the GSTT1(+) genotype (0,43±0,13%) as in the patients with the 
GSTT1(-) genotype (0,21±0,07%). In smoking patients the level of 
cells with micronuclei in PBL did not differ signiﬁcantly in carriers 
of the GSTT1(+) genotype (0,32±0,05%) and the GSTT1(-) genotype 
(0,29±0,09%). Some authors associate the low number cells with chro-
mosome aberrations in smoking patients and GSTT1 (-) carriers with 
higher enzyme expression, involved in repair of DNA damages.
Statistically signiﬁcant excess of the group average level of cells with 
micronuclei was shown in nontumoral tissue of smoking patients 
with the GSTT1(-) (0,57±0,08%) over those with the GSTT1(+) 
(0,33±0,04%). In non-smoking patients, the level of cells with 
micronuclei did not differ in GSTT1(-) - 0,30±0,02% and GSTT1(+)- 
0,38±0,14%. Damaging effect of tobacco smoke carcinogens directly 
on lung tissue in smokers is one of explanations of this fact that in 
combination with availability of mutant gene alleles of detoxication 
enzymes results in high probability of emerging cytogenetic injuries 
just in lung tissue. 
